Pharmacological rationale for choosing a drug containing potassium and magnesium citrate
DOI: 10.32364/2587-6821-2025-9-9-21
A.S. Dukhanin1, A.G. Chuvichkina2
1Pirogov Russian National Research Medical University, Moscow, Russian Federation
2Nizhpharm JSC, Nizhny Novgorod, Russian Federation
Aim: to perform a comparative analysis of the atomic release profiles of potassium and magnesium from three tablet formulations: the nutraceutical CardioM Potassium Magnesium and two medicinal products.
Materials and Methods: atomic absorption spectrometry was performed to assess dissolution of the samples in three media with pH values of 1.0, 4.5, and 6.8. This method was chosen for its capacity to determine the content of potassium and magnesium atoms regardless of the chemical form of the metal (citrate, aspartate, orotate, or lactate). Concentrations were calculated by the calibration curve method.
Results: in two of the media (pH 1.0 and pH 4.5), maximum release of potassium and magnesium atoms from the comparison drugs was achieved by 30 minutes and remained stable thereafter. For the CardioM Potassium Magnesium nutraceutical, the release profile was characterized by a progressive, near-linear increase in K+ and Mg2+ ion concentrations over time. In the pH 6.8 medium, metal atom release began at 15 minutes and later; however, by 60 minutes, the concentrations of potassium and magnesium released from CardioM Potassium Magnesium exceeded those observed with the comparison drugs.
Conclusion: based on the selected dose, solubility characteristics of the citrate form, and the extent and kinetics of atom release from the tablet formulation, intake of CardioM Potassium Magnesium may be considered an effective approach for the prevention of potassium and magnesium deficiency states in therapeutic and cardiological practice.
Keywords: intracellular magnesium, intracellular potassium, magnesium and potassium citrate, dissolution test, atomic absorption spectrometry.
For citation: Dukhanin A.S., Chuvichkina A.G. Pharmacological rationale for choosing a drug containing potassium and magnesium citrate. Russian Medical Inquiry. 2025;9(9):682–687 (in Russ.). DOI: 10.32364/2587-6821-2025-9-9-21
About the author:
Aleksander S. Dukhanin — Dr. Sc. (Med.), Professor, Professor of the Department of Molecular Pharmacology and Radiobiology, Pirogov Russian National Research Medical University; 1, Ostrovityanova str., Moscow, 117997, Russian Federation; ORCID iD 0000-0003-2433-7727
Alexandra G. Chuvichkina — C. Sc. (Pharm.), Head of the Department of Transfer and Contract Production, Nizhpharm JSC; 7, Salganskaya str., Nizhny Novgorod, 603950, Russian Federation; ORCID iD 0009-0006-4779-9018
Funding source: the article was prepared with the support of Nizhpharm JSC. The opinion of the authors may not coincide with the opinion of the company.
There is no conflict of interest.
Received 30.06.2025.
Revised 23.07.2025.
Accepted 15.08.2025.
2. Touyz R.M., De Baaij J.H.F., Hoenderop J.G.J. Magnesium Disorders. N Engl J Med. 2024;6;390(21):1998–2009. DOI: 10.1056/NEJMra1510603
3. Zacchia M., Abategiovanni M.L., Stratigis S., Capasso G. Potassium: From Physiology to Clinical Implications. Kidney Dis (Basel). 2016;2(2):72–79. DOI: 10.1159/000446268
4. Al Alawi A.M., Al Badi A., Al Huraizi A., Falhammar H. Magnesium: The recent research and developments. Adv Food Nutr Res. 2021;96:193–218. DOI: 10.1016/bs.afnr.2021.01.001
5. Mathew A.A., Panonnummal R. ‘Magnesium'-the master cation-as a drug-possibilities and evidences. Biometals. 2021;34(5):955–986. DOI: 10.1007/s10534-021-00328-7
6. McCormick J.A., Topf J., Tomacruz I.D., Grimm P.R. A New Understanding of Potassium's Influence Upon Human Health and Renal Physiology. Adv Kidney Dis Health. 2023;30(2):137–147. DOI: 10.1053/j.akdh.2023.01.001
7. Su X.T., Yang C.L., Ellison D.H. Kidney Is Essential for Blood Pressure Modulation by Dietary Potassium. Curr Cardiol Rep. 2020;22(10):124. DOI: 10.1007/s11886-020-01359-1
8. Breen C., Ryan M., Gibney M.J., O'Shea D. Diabetes-related nutrition knowledge and dietary intake among adults with type 2 diabetes. Br J Nutr. 2015;114(3):439–447. DOI: 10.1017/S0007114515002068
9. Qu X., Jin F., Hao Y. et al. Magnesium and the risk of cardiovascular events: a meta-analysis of prospective cohort studies. PLoS One. 2013;8(3):e57720. DOI: 10.1371/journal.pone.0057720
10. Zhao B., Zeng L., Zhao J. et al. Association of magnesium intake with type 2 diabetes and total stroke: an updated systematic review and meta-analysis. BMJ Open. 2020;10(3):e032240. DOI: 10.1136/bmjopen-2019-032240
11. Pickering R.T., Bradlee M.L., Singer M.R., Moore L.L. Higher Intakes of Potassium and Magnesium, but Not Lower Sodium, Reduce Cardiovascular Risk in the Framingham Offspring Study. Nutrients. 2021;13(1):269. DOI: 10.3390/nu13010269
12. Bobrowicz M., Pachucki J., Popow M. Hypomagnesaemia leading to parathyroid dysfunction, hypocalcaemia, and hypokalaemia as a complication of long-term treatment with a proton pump inhibitor — a literature review. Endokrynol Pol. 2024;75(4):359–365. DOI: 10.5603/ep.98576
13. Ruml L.A., Pak C.Y. Effect of potassium magnesium citrate on thiazide-induced hypokalemia and magnesium loss. Am J Kidney Dis. 1999;34(1):107–113. DOI: 10.1016/s0272-6386(99)70115-0
14. Vongpatanasin W., Giacona J.M., Pittman D. et al. Potassium Magnesium Citrate Is Superior to Potassium Chloride in Reversing Metabolic Side Effects of Chlorthalidone. Hypertension. 2023;80(12):2611–2620. DOI: 10.1161/HYPERTENSIONAHA.123.21932
15. Барышникова Г.А., Чорбинская С.А., Степанова И.И., Блохина О.Е. Дефицит калия и магния, их роль в развитии сердечно-сосудистых заболеваний и возможность коррекции. Consilium Medicum. 2019;21(1):67–73. DOI: 10.26442/20751753.2019.1.190240Baryshnikova G.A., Chorbinskaya S.A., Stepanova I.I., Blokhina O.E. Potassium and magnesium deficiency, its role in cardiovascular disease development and possibilities of correction. Consilium Medicum. 2019;21(1):67–73 (in Russ.). DOI: 10.26442/20751753.2019.1.190240
16. Прокопович О.А., Калачева А.Г., Торшин И.Ю. и др. Перспективы использования растворимых органических форм магния. Медицинский совет. 2015;11:90–97. DOI: 10.21518/2079-701X-2015-11-90-97Prokopovich O.A., Kalacheva A.G., Torshin I.Y. et al. Prospects for the use of soluble organic magnesium. Medical Council. 2015;(11):90–97 (in Russ.). DOI: 10.21518/2079-701X-2015-11-90-97
17. Духанин А.С. Препараты изотретиноина: от активной молекулы к терапевтическому эффекту. Клиническая дерматология и венерология. 2019;18(3):271–278.Dukhanin A.S. Isotretinoin drugs: from active molecule to therapeutic effect. Russian Journal of Clinical Dermatology and Venereology. 2019;18(3):271–278 (in Russ.).
18. Ranade V.V., Somberg J.C. Bioavailability and pharmacokinetics of magnesium after administration of magnesium salts to humans. Am J Ther. 2001;8(5):345–357. 10.1097/00045391-200109000-00008
19. Леонова М.В. Новые лекарственные формы и системы доставки лекарственных средств: особенности пероральных лекарственных форм. Часть 2. Лечебное дело. 2009;3:18–26.Leonova M.V. New medicines and drug delivery systems: the peculiarities of oral forms. Part 2. Lechebnoe delo. 2009;3:18–26 (in Russ.).
This work is licensed under a Creative Commons «Attribution» 4.0 License.
